Vasomedical's EECP Therapy for the Treatment of Heart Failure Presented at the Annual Heart Failure Society of America Scientific Meeting; Data from the International EECP Patient Registry Demonstrates Value of Therapy.

WESTBURY, N.Y. -- Vasomedical, Inc. (NASDAQ SC: VASO), a leader in the non-invasive treatment and management of cardiovascular diseases, announced today that two separate abstracts on the role of EECP(R) therapy as a treatment for patients with heart failure were presented at the Heart Failure Society of America (HFSA) Annual Scientific Session.

William Lawson, M.D., Chief of the Department of Cardiology at University Medical Center at Stony Brook, NY was the lead author on a study examining the effect of the length of EECP treatments on patients from the International EECP Patient Registry (IEPR) with a history of heart failure. The study demonstrates that patients who complete at least 30 hours of EECP treatment sessions have better outcomes immediately following and for at least one year post-treatment than patients who complete an abbreviated course of less than 10 hours of EECP therapy.

Ozlem Soran, M.D., Assistant Research Professor at the Cardiovascular Institute at the University of Pittsburgh Medical Center presented an analysis of patients from the IEPR with left ventricular dysfunction (LVD), or loss of pumping capacity of the heart. This analysis concludes that LVD patients who obtain higher diastolic augmentation during EECP treatment receive better short and long-term cardiovascular related outcomes. Diastolic augmentation is a simple ratio of patient blood pressures achieved during EECP and can serve as an indicator of their response to treatment.

The 8th annual HFSA meeting held in Toronto, Canada September 12th - 15th brought together nearly 3,000 physicians, scientists, epidemiologists, healthcare workers, and others involved in the continuum of care for patients with heart failure. The two and a half day conference included plenary sessions, state-of-the-art symposia, invited lecturers and debates, how-to sessions, and poster presentations of accepted abstracts.

Heart failure affects over 5 million Americans today with approximately 550,000 newly diagnosed cases each year. It is the most frequent cause of hospitalization for those over 65 years of age and the single largest financial drain on the Medicare system. The disease remains one of the most expensive healthcare problems in the United States and other developed countries. Vasomedical's EECP therapy is indicated for use as a treatment for heart failure.

About EECP(R) Therapy - Enhanced External Counterpulsation 

Vasomedical's advanced, state-of-the-art EECP(R) external counterpulsation system is comprised of an air compressor, a computer console, a set of cuffs and a treatment table. To receive treatment, patients lie down on the table and have their calves and lower and upper thighs wrapped in the cuffs. The system, which is synchronized to the individual patient's cardiac cycle, inflates the cuffs with air to create external pressure when the heart is resting (diastole) and deflates the cuffs just before the heart beats (systole). The system's action, which pulses counter to the heart's beating, increases blood flow to the heart muscle, decreases the heart's workload and creates a greater oxygen supply for the heart muscle while lowering the heart's need for oxygen.

Treatment is typically given in 35 one-hour-sessions over seven weeks; the benefits have been shown to persist for years. Researchers hypothesize that EECP(R) therapy may work by promoting the release of beneficial growth factors, by improving the neurohormonal milieu within blood vessels and by encouraging the proliferation of collateral blood vessels. Vasomedical's EECP(R) systems are the only counterpulsation devices shown in clinical studies published in major peer-reviewed journals to provide improvements in exercise capacity, peak oxygen consumption and quality of life.

About Vasomedical

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP(R) external counterpulsation systems based on the Company's proprietary technology. EECP(R) therapy is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and may restore systemic vascular function. The Company provides hospitals, clinics and private practices with EECP(R) equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. EECP(R) is a registered trademark for Vasomedical's enhanced external counterpulsation system. Additional information is available on the Company's website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate", "believes", "estimate", "expect", "should", "intend", "projects", "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.